跳至主要内容
临床试验/CTRI/2025/09/094510
CTRI/2025/09/094510尚未招募不适用

Effectiveness of Bleomycin-Lipiodol Transarterial Chemoembolization Therapy in Hepatic Hemangioma: A Pilot Non-Randomised Controlled Trial

未提供1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年9月20日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
20
试验地点
1
主要终点
Size reduction

研究概览

简要总结

This study is a non randomised, parallel arms, single centre, active-controlled trial for assessment of the effectiveness of Bleomycin Lipiodol Transarterial Chemoembolization (TACE) in patients with giant or symptomatic hepatic hemangioma that will be conducted in India at a single tertiary care centre (All India Institute of Medical Sciences, New Delhi), in comparison to patients receiving only symptomatic medical management . The primary outcome will be measurement of size reduction at 6 months. The secondary outcomes will be to assess symptomatic resolution at 6 months and to assess the post procedural complications associated with TACE.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Age more than 18 years Patients with imaging diagnosis of typical hemangioma of size more than 5 cm or who are symptomatic Patients willing to give consent for the study.

排除标准

  • Age less than 18 years Pregnant patients Patients with asymptomatic Hepatic Hemangioma measuring less than 5 cm Patients diagnosed with suspected Hemangioma with imaging revealing alternate diagnosis.
  • Patients who have received any form of treatment in past for Hepatic Hemangioma.

结局指标

主要结局

Size reduction

时间窗: 6 months

次要结局

  • Procedural complications(Post procedural period)
  • Symptomatic resolution(6 months)

研究者

发起方
未提供
责任方
Principal Investigator
主要研究者

Dr Kaushal Jain

All India Institute of Medical Sciences, New Delhi

研究点 (1)

Loading locations...

相似试验

Response of transarterial chemo embolisation with... | 临床试验